Yoshiyuki Taoda

This inventor holds 32 USPTO granted patents and 27 published patent applications, plus 5 CIPO patents and 21 EPO patents, primarily in HIV Inhibitors. Top assignees: Shionogi Company Limited, Viiv Healthcare Company, Hokkaido University. Active years: 2010-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Yoshiyuki Taoda. Retrieved from https://idiyas.com/inventor/yoshiyuki-taoda

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 32 (Patent Applications = 27)

% Patents Active = 87.5

CIPO Patents = 5 (Patent Applications = 3)

EPO Patents = 21 (Patent Applications = 25)

Average Co-Inventor Count = 4.1

ph-index = 10

Forward Citations = 336(Granted Patents)

Location History:

Toyonaka, JP (2015)
Osaka, JP (2010 - 2023)

Company Filing History:

31 out of 1,001

Shionogi Company Limited

patents

10 out of 43

Viiv Healthcare Company

where one patent can have more than one assignee

Years Active: 2010-2026

Loading Chart...

Areas of Expertise:

HIV Integrase Inhibitors

Polycyclic Derivatives

Arenavirus Inhibitors

Pharmaceutical Compositions

Triazine Derivatives

Carbamoylpyridone

Antiviral Activity

Prodrugs

32 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12559474 - TRIAZINE DERIVATIVES HAVING VIRUS REPLICATION INHIBITORY ACTIVITY AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME (2026-02-24),

2. 12139489 - Polycyclic carbamoylpyridone derivative (2024-11-12),

3. 12098151 - Arenavirus growth inhibitor comprising polycyclic carbamoyl pyridone derivative (2024-09-24),

4. 11814368 - Triazine derivatives having virus replication inhibitory activity and pharmaceutical composition comprising the same (2023-11-14),

5. 11649236 - Polycyclic carbamoylpyridone derivative (2023-05-16),

6. 11492352 - Arenavirus growth inhibitor comprising polycyclic carbamoylpyridone derivative (2022-11-08),

7. 11453669 - Polycyclic pyridone derivative (2022-09-27),

8. 11267823 - Substituted 1,2,3,3a,4,5,7,9,13,13a-decahydropyrido[1',2′:4,5]pyrazino[1,2-a]pyrrolo[1,2-c]pyrimidines having HIV integrase inhibitory activity (2022-03-08),

9. 10927129 - N-[(2,4-difluorophenyl)methyl]-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-hexahydro[1,3] oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide having HIV integrase inhibitory activity (2021-02-23),

10. 10202379 - Substituted polycyclic carbamoyl pyridone derivative prodrug (2019-02-12),

11. 9815835 - Substituted polycyclic carbamolypyridone derivative (2017-11-14),

12. 9758515 - Substituted polycyclic carbamoyl pyridone derivative prodrug (2017-09-12),

13. 9527840 - Substituted-quinoxaline-type piperidine compounds and the uses thereof (2016-12-27),

14. 9469638 - Substituted polycyclic carbamoylpyridone derivative (2016-10-18),

15. 9365587 - Synthesis of carbamoylpyridone HIV integrase inhibitors and intermediates (2016-06-14),

Title: Yoshiyuki Taoda: Pioneering Innovations in Antiviral Pharmaceuticals

Introduction:

Yoshiyuki Taoda, a renowned inventor hailing from Osaka, Japan, has made significant strides in the field of pharmaceuticals with his groundbreaking patented inventions. With a total of 29 patents to his name, Taoda's contributions have had a profound impact on the realm of antiviral medications.

Latest Patents:

Among his latest patents, Yoshiyuki Taoda has introduced revolutionary compounds with virus replication inhibitory activity. One such patent involves triazine derivatives that exhibit coronavirus 3 CL protease inhibitory activity, along with a pharmaceutical composition comprising these compounds. Additionally, Taoda's work includes a polycyclic carbamoylpyridone derivative, showcasing his prowess in developing novel pharmaceutical solutions.

Career Highlights:

Throughout his illustrious career, Yoshiyuki Taoda has worked with prominent companies such as Shionogi & Company Limited and ViiV Healthcare Company. His expertise and dedication in the pharmaceutical sector have been instrumental in driving innovation and progress within the industry.

Collaborations:

Taoda has collaborated with esteemed colleagues in his professional journey, including notable individuals such as Brian Alvin Johns and Takashi Kawasuji. Together, they have collectively contributed to the development of cutting-edge pharmaceutical technologies and advancements in antiviral treatments.

Conclusion:

In conclusion, Yoshiyuki Taoda's inventive spirit and commitment to advancing antiviral pharmaceuticals have solidified his reputation as a trailblazing inventor in the field. His patented innovations continue to shape the landscape of antiviral medications, offering hope and healing to individuals around the globe.

Profile summary based on public USPTO records.